← Leaderboards
Celine M Vachon
Mayo Clinic Coll Of Medicine, Rochester
$17,209,085
Attributed
$27,933,124
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,933,124 · 15
By mechanism
R01$20,535,416 · 8
U01$2,826,486 · 1
P50$1,754,710 · 2
R25$1,720,912 · 1
R21$1,095,600 · 3
Top collaborators
- Karla M Kerlikowske18 shared
- Elizabeth E Brown10 shared
- Despina Kontos8 shared
- Shaji Kunnathu Kumar5 shared
- Gloria M. Petersen5 shared
- Elad Ziv2 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- S Vincent Rajkumar$8,690,866
- Richard M Weinshilboum$55,444,344
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMammographyVariantBreast DensityWomanBreast Cancer Risk FactorRisk FactorsClinicCohortMalignant Breast NeoplasmBaseCancer RiskFutureDensityBreastScreeningTumorInsightMonitorCategoriesGenesAreaImageInnovation
Grant awards (60)
Evaluation of novel tomosynthesis density measures in breast cancer risk prediction$671,511
R01 · FY2025 · CA · contact PI
Impact of Genetic susceptibility along the continuum from MGUS to MM$659,222
U01 · FY2025 · CA · contact PI
Developmental Research Program$160,747
P50 · FY2025 · CA · contact PI
Evaluation of novel tomosynthesis density measures in breast cancer risk prediction$637,516
R01 · FY2024 · CA · contact PI
Impact of Genetic susceptibility along the continuum from MGUS to MM$621,962
U01 · FY2024 · CA · contact PI
Developmental Research Program$152,030
P50 · FY2024 · CA · contact PI
Evaluation of novel tomosynthesis density measures in breast cancer risk prediction$701,775
R01 · FY2023 · CA · contact PI
Impact of Genetic susceptibility along the continuum from MGUS to MM$650,438
U01 · FY2023 · CA · contact PI
Developmental Research Program$148,874
P50 · FY2023 · CA · contact PI
Impact of Genetic susceptibility along the continuum from MGUS to MM$694,881
U01 · FY2022 · CA · contact PI
Impact of Genetic susceptibility along the continuum from MGUS to MM (Supplement)$199,983
U01 · FY2022 · CA · contact PI
Radiomic phenotypes of breast parenchyma and association with breast cancer risk and detection$622,266
R01 · FY2021 · CA · contact PI
Radiomic phenotypes of breast parenchyma and association with breast cancer risk and detection$632,591
R01 · FY2020 · CA · contact PI
Behavioral and Psychological Impact of Returning Breast Density Results to Latinas$457,263
R01 · FY2020 · MD · contact PI
Radiomic phenotypes of breast parenchyma and association with breast cancer risk and detection$620,863
R01 · FY2019 · CA · contact PI
Behavioral and Psychological Impact of Returning Breast Density Results to Latinas$454,024
R01 · FY2019 · MD · contact PI
Radiomic phenotypes of breast parenchyma and association with breast cancer risk and detection$655,893
R01 · FY2018 · CA · contact PI
Molecular characterization of myeloma and related asymptomatic precursor states$263,388
R01 · FY2018 · CA
Mayo Cancer Genetic Epidemiology Training Program$64,301
R25 · FY2018 · CA · contact PI
Molecular characterization of myeloma and related asymptomatic precursor states$1,043,373
R01 · FY2017 · CA
Radiomic phenotypes of breast parenchyma and association with breast cancer risk and detection$691,211
R01 · FY2017 · CA · contact PI
Automated Density Measures for Estimating Breast Cancer Risk and Therapy Response$418,772
R01 · FY2017 · CA · contact PI
Mayo Cancer Genetic Epidemiology Training Program$378,760
R25 · FY2017 · CA · contact PI
Automated Density Measures for Estimating Breast Cancer Risk and Therapy Response$767,193
R01 · FY2016 · CA · contact PI
Mayo Cancer Genetic Epidemiology Training Program$515,871
R25 · FY2016 · CA · contact PI
Molecular characterization of myeloma and related asymptomatic precursor states$431,508
R01 · FY2016 · CA
Influence of germ line genetic variation on myeloma progression and survival$176,240
R21 · FY2016 · CA
Automated Density Measures for Estimating Breast Cancer Risk and Therapy Response$635,879
R01 · FY2015 · CA · contact PI
Molecular characterization of myeloma and related asymptomatic precursor states$616,560
R01 · FY2015 · CA
Mayo Cancer Genetic Epidemiology Training Program$469,757
R25 · FY2015 · CA · contact PI
Influence of germ line genetic variation on myeloma progression and survival$230,502
R21 · FY2015 · CA
Identifying high risk mammographic features in women with benign breast dise$175,373
R21 · FY2015 · CA · contact PI
Molecular characterization of myeloma and related asymptomatic precursor states$642,027
R01 · FY2014 · CA
Automated Density Measures for Estimating Breast Cancer Risk and Therapy Response$580,457
R01 · FY2014 · CA · contact PI
Risk factors for breast cancer molecular subtypes$319,653
R01 · FY2014 · CA · contact PI
Mayo Cancer Genetic Epidemiology Training Program$292,223
R25 · FY2014 · CA · contact PI
Identifying high risk mammographic features in women with benign breast dise$225,661
R21 · FY2014 · CA · contact PI
Automated Density Measures for Estimating Breast Cancer Risk and Therapy Response$621,043
R01 · FY2013 · CA · contact PI
Risk factors for breast cancer molecular subtypes$505,034
R01 · FY2013 · CA · contact PI
Risk factors for breast cancer molecular subtypes$543,609
R01 · FY2012 · CA · contact PI
Identifying Genes for Mammographic Breast Density$380,420
R01 · FY2012 · CA · contact PI
Risk factors for breast cancer molecular subtypes$554,557
R01 · FY2011 · CA · contact PI
Identifying Genes for Mammographic Breast Density$410,717
R01 · FY2011 · CA · contact PI
Risk factors for breast cancer molecular subtypes$630,556
R01 · FY2010 · CA · contact PI
Identifying Genes for Mammographic Breast Density$613,475
R01 · FY2010 · CA · contact PI
Identifying Genes for Mammographic Breast Density$487,958
R01 · FY2009 · CA · contact PI
Aromatase Inhibitors, Breast Density and Plasma Steroid Hormones$315,533
P50 · FY2009 · CA · contact PI
Identifying Genes for Mammographic Breast Density$269,744
R01 · FY2009 · CA · contact PI
Identifying Genes for Mammographic Breast Density$570,954
R01 · FY2008 · CA · contact PI
Aromatase Inhibitors, Breast Density and Plasma Steroid Hormones$240,988
P50 · FY2008 · CA · contact PI
A Mayo Cohort Study of Mammographic Breast Density$589,224
R01 · FY2007 · CA · contact PI
P-4: Aromatase Inhibitors, Mammographic Density and Plasma Steroid Hormones$332,725
P50 · FY2007 · CA · contact PI
A Mayo Cohort Study of Mammographic Breast Density$607,576
R01 · FY2006 · CA · contact PI
P-4: Aromatase Inhibitors, Mammographic Density and Plasma Steroid Hormones$207,067
P50 · FY2006 · CA · contact PI
A Mayo Cohort Study of Mammographic Breast Density$630,354
R01 · FY2005 · CA
P-4: Aromatase Inhibitors, Mammographic Density and Plasma Steroid Hormones$196,746
P50 · FY2005 · CA
A Mayo Cohort Study of Mammographic Breast Density$629,933
R01 · FY2004 · CA
A Mayo Cohort Study of Mammographic Breast Density$626,539
R01 · FY2003 · CA
Anti-melanoma Immune responses in Melanoma development$144,500
R21 · FY2003 · CA
Anti-melanoma Immune responses in Melanoma development$143,324
R21 · FY2002 · CA